Literature DB >> 3534474

Prolymphocytoid transformation of CLL: a clinical and immunological study of 22 cases.

A N Stark, H J Limbert, B E Roberts, R A Jones, C S Scott.   

Abstract

The clinical, morphological and immunological features of 22 cases of chronic lymphocytic leukaemia in 'prolymphocytoid' transformation (CLL-Pro) are reported. Immunophenotypic patterns in CLL-Pro differ from CLL by the appearance of significant (greater than 15%) FMC7-positive components and/or increased SIg densities in most cases. Membrane TU1 and MRBC receptor expression was similar to that found in typical CLL. Morphologically, all cases showed a mixture of small lymphocytes and larger nucleolated 'prolymphocytes' although the degree of prolymphocytoid change was unrelated to immunological patterns. Clinically, the cases behaved in a very heterogeneous fashion, with some patients dying rapidly following transformation despite treatment, while others even if untreated had a long, stable and relatively benign course. It was not possible to predict which patients would do badly from immunological or morphological features but the presence of more than one involved lymph node site and the occurrence of B-symptoms appeared to identify a group that did badly. Immunological assessments were however important in therapeutic terms, drawing distinction between CLL-Pro variants and prolymphocytic leukaemia (PLL).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534474     DOI: 10.1016/0145-2126(86)90241-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Nucleolar organiser regions in lymphocytes of patients with chronic lymphocytic leukaemia.

Authors:  P Kaur; D W Milligan; J Crocker
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

2.  Cell surface expression of beta 2-microglobulin (beta 2m) correlates with stages of differentiation in B cell tumours.

Authors:  R A Jones; C S Scott; D R Norfolk; A N Stark; J A Child
Journal:  J Clin Pathol       Date:  1987-05       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.